Literature DB >> 24869760

Effects of oxymatrine on the apoptosis and proliferation of gallbladder cancer cells.

Xiang-Song Wu1, Tian Yang, Jun Gu, Mao-Lan Li, Wen-Guang Wu, Hao Weng, Qian Ding, Jia-Sheng Mu, Run-Fa Bao, Yi-Jun Shu, Yang Cao, Xu-an Wang, Qi-Chen Ding, Ping Dong, Shun-Feng Xie, Ying-Bin Liu.   

Abstract

Gallbladder carcinoma is the most common malignancy of the biliary tract and is associated with a very poor outcome. The aim of the present study was to investigate the effects of oxymatrine (OM) on gallbladder cancer cells and the possible mechanism of its effects. The effects of OM on the proliferation of gallbladder cancer cells (GBC-SD and SGC-996) were investigated using cell counting kit-8 and colony formation assays. Annexin V/propidium iodide double staining was performed to investigate whether OM could induce apoptosis in gallbladder cancer cells. The mitochondrial membrane potential (ΔΨm) and expression of apoptosis-associated proteins were evaluated to identify a mechanism for the effects of OM. In addition, the RNA expression of relevant genes was measured by qRT-PCR using the SYBR Green method. Finally, a subcutaneous implantation model was used to verify the effects of OM on tumor growth in vivo. We found that OM inhibited the proliferation of gallbladder cancer cells. In addition, Annexin V/propidium iodide double staining showed that OM induced apoptosis after 48 h and the ΔΨm decreased in a dose-dependent manner after OM treatment. Moreover, the activation of caspase-3 and Bax and downregulation of Bcl-2 and nuclear factor κB were observed in OM-treated cells. Finally, OM potently inhibited in-vivo tumor growth following subcutaneous inoculation of SGC-996 cells in nude mice. In conclusion, OM treatment reduced proliferation and induced apoptosis in gallbladder cancer cells, which suggests that this drug may serve as a novel candidate for adjuvant treatment in patients with gallbladder cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24869760     DOI: 10.1097/CAD.0000000000000124

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  6 in total

1.  Oxymatrine Sensitizes the HaCaT Cells to the IFN-γ Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.

Authors:  Chun-Jie Gao; Pei-Jun Ding; Li-Li Yang; Xu-Feng He; Meng-Jiao Chen; Dong-Ming Wang; Yan-Xin Tian; Hui-Min Zhang
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

2.  HMGB1-mediated autophagy decreases sensitivity to oxymatrine in SW982 human synovial sarcoma cells.

Authors:  Yongsong Cai; Peng Xu; Le Yang; Ke Xu; Jialin Zhu; Xiaoqing Wu; Congshan Jiang; Qiling Yuan; Bo Wang; Yuanbo Li; Yusheng Qiu
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

Review 3.  Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action.

Authors:  Thazin Nwe Aung; Zhipeng Qu; R Daniel Kortschak; David L Adelson
Journal:  Int J Mol Sci       Date:  2017-03-17       Impact factor: 5.923

Review 4.  Recent Advances in Herbal Medicines for Digestive System Malignancies.

Authors:  Jiyao Sheng; Xiaohan Zou; Ziqian Cheng; Yien Xiang; Wei Yang; Yang Lin; Ranji Cui
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

5.  Oxymatrine inhibits the migration and invasion of hepatocellular carcinoma cells by reducing the activity of MMP-2/-9 via regulating p38 signaling pathway.

Authors:  Kunlun Chen; Pengfei Zhu; Jianwen Ye; Yuan Liao; Zhicheng Du; Fangfang Chen; He Juanjuan; Shaojin Zhang; Wenlong Zhai
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

6.  Oxymatrine exhibits anti-tumor activity in gastric cancer through inhibition of IL-21R-mediated JAK2/STAT3 pathway.

Authors:  Yanxia Huang; Jing Zhang; Ge Wang; Xiaoyu Chen; Rui Zhang; Hui Liu; Jinshui Zhu
Journal:  Int J Immunopathol Pharmacol       Date:  2018 Jan-Dec       Impact factor: 3.219

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.